Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML): Outcome of discontinuation of imatinib therapy after achieving a molecular remission

Because of the teratogenicity data in rats, it is recommended that women treated with imatinib should be aware of the potential teratogenicity of imatinib and effective contraception should be used during imatinib therapy to prevent pregnancy. We describe successful pregnancy and delivery, without a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2005-08, Vol.29 (8), p.971-973
Hauptverfasser:	Ali, Rıdvan, Özkalemkaş, Fahir, Özçelik, Tülay, Özkocaman, Vildan, Ozan, Ülkü, Kimya, Yalçın, Köksal, Nilgün, Gülten, Tuna, Yakut, Tahsin, Tunalı, Ahmet
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Benzamides Chronic myelogenous leukemia Female Humans Imatinib Imatinib Mesylate Infant, Newborn Labor, Induced Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Piperazines - adverse effects Piperazines - therapeutic use Pregnancy Pregnancy Complications, Neoplastic - drug therapy Pyrimidines - adverse effects Pyrimidines - therapeutic use Recurrence Remission Induction Treatment Outcome Withholding Treatment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!